Source comparison
CJC-1295/Ipamorelin vs Other Growth Hormone Secretagogues: Research Application Comparison
The choice between CJC-1295/Ipamorelin and alternative growth hormone secretagogues depends on study objectives. Pulse kinetics, half-life, receptor selectivity, and secondary endocrine effects all vary significantly across peptide classes. CJC-1295/Ipamorelin
This comparison does not assign a generated winner or score.
- The choice between CJC-1295/Ipamorelin and alternative growth hormone secretagogues depends on study objectives. Pulse kinetics, half-life, receptor selectivity, and secondary endocrine effects all vary significantly across peptide classes.
- CJC-1295/Ipamorelin
- Dual GHRH + ghrelin receptor agonism
- 6–8 days (CJC) / 2 hours (Ipa)
- Sustained baseline + high-amplitude pulses
- Minimal cortisol/prolactin elevation
- Long-duration studies requiring physiologic GH patterns with minimal HPA axis disruption
- Ipamorelin (standalone)
- Selective GHSR-1a agonist
- ~2 hours
- Short, high-amplitude pulses
- Highly selective. No cortisol or prolactin
- Acute GH response studies, appetite signaling research, short-duration protocols
- Sermorelin
- GHRH analog (no DAC modification)
- ~10 minutes
- Brief pulses, rapid clearance
- Minimal
- Studies requiring transient GH elevation without sustained receptor occupancy
- MK-677 (Ibutamoren)
- Oral ghrelin mimetic
- 24 hours
- Sustained elevation, blunted pulsatility
- Increased appetite, mild insulin resistance
- Chronic GH elevation studies, cachexia models, oral administration convenience
- Hexarelin
- Non-selective GHSR agonist
- ~70 minutes
- Very high-amplitude pulses
- Significant cortisol and prolactin elevation
- Maximal GH output studies where HPA axis activation is acceptable
- GHRP-2
- ~20 minutes
- Moderate-amplitude pulses
- Moderate cortisol elevation
- Studies examining HPA-GH interaction, cost-sensitive protocols
- CJC-1295/Ipamorelin sits in a unique position: it produces GH kinetics closer to endogenous secretion than any single-agent alternative while maintaining receptor selectivity that minimizes confounding endocrine variables. Hexarelin produces higher peak GH levels, but the concurrent cortisol and prolactin spikes make it unsuitable for studies examining pure growth hormone effects on metabolism or tissue repair. MK-677 offers oral bioavailability and once-daily dosing, but the sustained, non-pulsatile GH elevation it produces doesn't replicate natural secretion patterns and introduces appetite changes that confound body composition studies.
- Sermorelin, the unmodified GHRH analog, was a predecessor to CJC-1295. It binds the same receptor but lacks the DAC modification that extends half-life. The result is a GH pulse that peaks within 15–30 minutes and returns to baseline within 90 minutes. For researchers studying the acute signaling events triggered by GHRH receptor activation, Sermorelin offers temporal precision that CJC-1295's prolonged action would obscure. But for multi-week protocols examining cumulative anabolic effects. Lean mass accretion, bone density changes, lipolysis. CJC-1295's sustained receptor occupancy eliminates the need for multiple daily injections.
- Real Peptides maintains inventory across the full growth hormone secretagogue spectrum, allowing researchers to match peptide kinetics to study design rather than adapting protocols to available compounds. You can explore receptor-selective options like Ipamorelin for appetite signaling studies, or examine GH-independent pathways using compounds like MOTS-C for mitochondrial research. Precision in peptide selection is precision in experimental design.